Pyloric, pseudopyloric, and spasmolytic polypeptide-expressing metaplasias in autoimmune gastritis: a case series of 22 Japanese patients

Yasuhiro Wada 1,2,3 · Shigemi Nakajima2 · Ryoji Kushima1 · Shizuki Takemura4,5 · Naoko Mori2 · Hiroshi Hasegawa2 · Takahisa Nakayama1 · Ken-ichi Mukaiho1 · Akiko Yoshida5 · Shinji Umano5 · Kazuo Yamamoto2 · Hiroyuki Sugihara1 · Kazunari Murakami3

Received: 15 September 2020 / Revised: 8 January 2021 / Accepted: 13 January 2021 / Published online: 30 January 2021
© The Author(s) 2021

Abstract
There are two types of pyloric gland-like metaplasia in the corpus of stomach: pyloric and pseudopyloric metaplasias. They show the same morphology as the original pyloric glands in H&E staining. Pseudopyloric metaplasia is positive for pepsinogen (PG) I immunohistochemically, whereas pyloric metaplasia is negative. Recently, spasmolytic polypeptide-expressing metaplasia (SPEM) is proposed for pyloric gland-like metaplasia mainly in animal experiments. SPEM expresses trefoil factor family 2 (TFF2) and is often considered synonymous with pseudopyloric metaplasia. We reviewed consecutive 22 Japanese patients with autoimmune gastritis (AIG) to investigate TFF2 expression in pyloric and pseudopyloric metaplasias by counting all pyloric gland-like glands in biopsy specimens taken from greater curvature of the middle corpus according to the Updated Sydney System. Pyloric metaplasia was seen in all the 22 cases, and pseudopyloric metaplasia was found in 15 cases. Of 1567 pyloric gland-like glands in all the cases, 1381 (88.1%) glands were pyloric metaplasia glands, and the remaining 186 (11.9%) glands were pseudopyloric metaplasia glands. TFF2 expression was observed in pyloric or pseudopyloric metaplasia glands in 20 cases. TFF2 expression was recognized in 409 of 1381 (26.9%) pyloric metaplasia glands and 27 of 186 (14.5%) pseudopyloric metaplasia glands (P<0.01, chi-square test). In conclusion, SPEM was not always the same as pseudopyloric metaplasia in human AIG, and the majority of metaplasia in AIG was not pseudopyloric but pyloric metaplasia.

Keywords
Autoimmune gastritis · Pseudopyloric metaplasia · Spasmolytic polypeptide-expressing metaplasia · Gastrin

Introduction
Metaplasia is a phenomenon in which one adult cell type is replaced by another adult cell type [1]. In stomach, various types of metaplasias have been described. Intestinal metaplasia is one of the representative metaplasias in the stomach which consists of large or small intestinal mucosa located in the places where gastric mucosa should have existed [1]. Pyloric/pseudopyloric metaplasia is another representative metaplasia which consists of pyloric gland mucosa located in the places where fundic gland mucosa should have existed [2–4]. Pancreatic acinar cell metaplasia is a cluster composed of pancreatic acinar cells in stomach [5–7].

Pyloric metaplasia is stained same as original pyloric gland mucosa with hematoxylin and eosin (H&E) and with immunohistochemical staining for MUC6. Pseudopyloric
metaplasia is also stained the same as original pyloric gland mucosa with H&E but positive for pepsinogen (PG) I immunohistochemically, whereas pyloric metaplasia is negative [3]. Unfortunately, in many papers, pyloric and pseudopyloric metaplasias have not been described separately and are often treated as collectively “pyloric or pseudopyloric metaplasia” [4].

Recently, trefoil factor family 2 (TFF2) expression in the stomach of animals has been used to designate something like spasmolytic polypeptide-expressing metaplasia (SPEM). Wang et al. have reported that an aberrant metaplastic lineage was found in fundic mucosa of mice infected with Helicobacter felis, and this metaplastic lineage expressed TFF2, reflecting regenerative changes in gastric mucosa [8–10]. Several reports have indicated that SPEM is a precancerous lesion of gastric carcinoma [11–14], whereas Graham and Zou suggested that the direct experimental evidence of SPEM to gastric cancer transition was minimal, and SPEM should not be used for studies in humans [15]. In many papers, SPEM is often considered synonymous with pseudopyloric metaplasia [16–20]. However, in Helicobacter pylori (H. pylori) gastritis, pyloric and pseudopyloric metaplasias did not always express TFF2 [4].

Autoimmune gastritis (AIG) is a chronic, progressive inflammatory disease which is characterized with marked destruction of parietal cells in gastric mucosa by autoimmune mechanisms resulting in decreased gastric acid secretion followed by hypergastrinemia via negative feedback reaction [21–23]. As AIG progresses, severe atrophy of fundic glands is also accompanied with various kinds of metaplasia, such as intestinal metaplasia, pyloric/pseudopyloric metaplasia, and pancreatic acinar cell metaplasia [24–30]. Therefore, AIG is one of the models to examine TFF2 expression in pyloric/pseudopyloric metaplasia.

In this study, we examined the numbers of TFF2 expressing glands in pyloric/pseudopyloric metaplasia glands and confirmed whether SPEM can be used for pseudopyloric metaplasia in human materials.

Materials and methods

Subjects

We retrospectively reviewed the biopsy specimens of consecutive 22 patients (7 male and 15 female) who underwent esophagogastroduodenoscopy and who were clinically and histopathologically diagnosed as AIG in Japan Community Healthcare Organization (JCHO) Shiga Hospital, Japan, between May 2012 and January 2020. Diagnosing criteria for AIG consisted of positivity of either serum anti-parietal cell or anti-intrinsic factor antibodies, accompanied with at least one of the following four items: increased serum gastrin, severe endoscopic gastric mucosal atrophy, strongly positive (3+) serum PG test, and decreased serum vitamin B12, and also being satisfied with histopathological criteria as described later. Serum gastrin, PG, and vitamin B12 were measured with Gastrin RIA Kit II (Fujirebio), ARCHITECT Pepsinogen I and II (Abbott Japan, Tokyo, Japan), and Beckman Coulter ACCESS B12 (Beckman Coulter), respectively.

In order to confirm the infection status of H. pylori, history about the past H. pylori tests and therapies was collected from the medical records. H. pylori tests included serum H. pylori antibody test (HpAb) (E-plate Eiken H. pylori antibody II, Eiken Kagaku, Tochigi, Japan), H. pylori stool antigen test (HpSA) (Meridian HpSA ELISA II, Fujirebio), urea breath test (UBT) (Ubit Tablets 100 mg, Otsuka Pharmaceutical, Tokyo, Japan; POCon, Otsuka Electronics, Osaka, Japan), histopathology (H&E staining and Giemsa staining), and culture for H. pylori. Serum anti-H. pylori was tentatively judged negative when the ELISA value was below 10.0 U/mL according to the manufacturer’s instruction. HpSA was tentatively judged positive with the value 0.120 or more and negative with the values less than 0.100. UBT was tentatively judged negative with the delta-13CO2 less than 2.0‰ and positive with the value 5.0‰ or more. Patients with clear evidence of current H. pylori infection with pathology or culture were determined “currently infected.” Those showing no evidence of infection by all the tests performed were diagnosed “not infected.” Those who had past eradication therapy were included in “past infected.” Other patients were diagnosed either of the above three status from the combination of multiple tests and their chronological changes. Therefore, patients with current H. pylori infection were not included in this study.

Histopathological examination of AIG

Biopsy specimens were collected from greater curvature of the middle corpus and antrum endoscopically by three-points biopsy or five-points biopsy. In three-points biopsy, we collected biopsy specimens from greater curvature of the middle corpus and antrum and lesser curvature of the angulus. In five-points biopsy, we collected biopsy specimens from greater curvature of the middle corpus and antrum, and lesser curvature of the middle corpus, angulus, and antrum according to the Updated Sydney System (USS). Among them, we evaluated specimens taken from greater curvature of the middle corpus and antrum in this study. USS proposes that “B2” and “A2” are the best biopsy sites to evaluate the histopathological status of fundic and antral mucosa, respectively [31]. Biopsy specimens of all patients were taken once per patient, and each specimen was put into separate vials. Biopsy specimens were immediately fixed in 10% neutral buffered
formalin for 24 h and embedded in paraffin. Fixed samples were serially sliced into 3-μm-thick sections and stained with H&E. According to the previous reports, the histopathology was classified into three stages with H&E-stained sections: early, florid, and end stages [24–28]. The early stage consisted of moderate inflammatory cell infiltration in the lamina propria and decreased parietal cells. The florid stage consisted of marked atrophy of fundic glands with diffuse lymphoplasmacytic infiltration. The end stage consisted of reduced inflammatory cell infiltrates and complete parietal cell loss [32]. AIG was comprehensively diagnosed by two pathologists with more than 20 years of diagnostic experience.

Inflammation, activity, atrophy, and intestinal metaplasia of greater curvature of the middle corpus were evaluated with the USS (0, none; 1, mild; 2, moderate; 3, marked) [31]. In addition, the lymphoid follicles and lymphocyte aggregation (LF/LA) were also examined and scored (0, none; 1, small lymphocyte aggregation; 2, 1 or 2 lymphoid follicles were observed; and 3, more than 3 lymphoid follicles were observed).

Evaluation of AIG with immunohistochemical staining

In AIG, gastrin cell hyperplasia is often recognized in the antrum [3]. On the other hand, linear and nodular types of enterochromaffin cell-like (ECL) cell hyperplasia are seen in the corpus in florid or end stages [26, 33]. Linear type is recognized as clusters of hyperplastic ECL cells lining in the glands and nodular type as clusters of ECL cells out of the glands in the lamina propria. In recent years, BCL-10 is reported to be positive in pancreatic acinar cell metaplasia [34, 35]. We counted the numbers of H+/K+-ATPase-positive cells, ECL cells, and gastrin cells per each section. Then, we measured the size of each section and we calculated the cell density per each section. Thus, the densities of parietal cells, ECL cells, and gastrin cells and the presence of gastric acinar cell metaplasia were examined in each immunohistochemically stained section.

For immunohistochemical examination, the following antibodies were used as primary antibodies: anti-H+/K+-ATPase α (1:10000; Medical & Biological Laboratories, Nagoya, Japan, cat. no. 024) for parietal cells, anti-chromogranin A (diluted; Roche, Basel, Switzerland, cat.760-2519) for ECL cells, anti-BCL-10 (1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA, cat. SC-5273) and anti-α-amylase (1:1000; Cell Signaling Technology, Danvers, MA, USA, cat. no. 3796) for pancreatic acinar cell metaplasia, and anti-gastrin (diluted; Dako, Glostrup, Denmark, cat. IR519) for gastrin cells. An automated immunostaining device was used for immunostaining (Ventana; Discovery XT, Roche Diagnostics K.K., Tokyo, Japan). Immunohistochemical examination was performed at Shiga University of Medical Science. Image analysis software (WinROOF2018; Mitani Corporation, Fukui, Japan) was used to measure the size of the section.

Evaluation of pyloric gland-like metaplasias

In the corpus mucosa, we classified pyloric gland-like glands into pyloric and pseudopyloric metaplasias. Briefly, anti-MUC6 (diluted; Cell Signaling Technology, cat.760-4390) and anti-PGI (1:40; BIO RAD, Hercules, CA, USA, cat.7240-1009) antibodies were used for the immunohistopathological differentiation of these metaplasias. Pyloric and pseudopyloric metaplasias were identified as in the following: MUC6-positive/PGI-negative for pyloric metaplasia and MUC6-positive/PGI-positive for pseudopyloric metaplasia. We also examined TFF2 expression in pyloric and pseudopyloric glands by anti-TFF2 antibody (1:600; Proteintech, Rosemont, IL, USA, cat.D031-3) with immunohistochemical staining. We counted the numbers of pyloric and pseudopyloric metaplasia glands in all the sections. Then, the numbers of TFF2 expressing glands in pyloric and pseudopyloric metaplasias were counted in all the sections.

Statistical analysis

The Mann-Whitney test was used to evaluate the densities of H+/K+-ATPase-positive parietal cells, ECL cells, and gastrin cells. The chi-square test was used to evaluate the TFF2-positive gland ratio between pyloric and pseudopyloric metaplasias. SPSS (Stats Guild Inc. Chiba, Japan) was used in each analysis, and a value of $P<0.05$ was considered significant.

Results

Histopathological evaluation of AIG

The mean USS scores in greater curvature of the middle corpus of 22 AIG subjects were as follows: atrophy 3.0 ± 0.0, inflammation 2.1 ± 0.2, activity 0.0 ± 0.0, intestinal metaplasia 1.0 ± 0.8, and LF/LA 1.3 ± 0.7. Histopathological staging revealed that there were no cases in the early stage, 4 cases in the florid stage, and 18 cases in the end stage (Fig. 1). In greater curvature of the middle corpus, H+/K+-ATPase-positive parietal cells were found in 6 of 22 cases (4 in florid and 2 in end stages), and the mean density of the cell was significantly greater in florid stage than that in end stage ($P<0.01$, Mann-Whitney test; Table 1). Chromogranin A-positive linear and nodular ECL cell hyperplasia was observed in all cases (Fig. 2). The mean cell density was not significantly different between florid and end stages in both linear and nodular types.
BCL-10-positive pancreatic acinar cell metaplasia was not observed in florid stage, but observed in 2 cases in end stage; 1 of the cases was also stained with α-amylase but the other was not (Fig. 2). Gastrin-positive cells were found in all cases in greater curvature of the antrum, but the mean density of the cell was not significantly different between florid and end stages (P=0.69, Mann-Whitney test; Table 1). Gastrin-

Table 1  Comparison of mean cell densities between stages of AIG

| Immunohistochemical cell type                           | Mean cell densities (cells/mm²) | p value* |
|---------------------------------------------------------|---------------------------------|----------|
|                                                                 | Stage of AIG                    |          |
|                                                          | Florid stage (N=4)              | End stage (N=18) |
| H⁺/K⁻-ATPase-positive cells in the corpus               | 11.18                           | 0.33     | <0.01    |
| Linear type ECL cells in the corpus                     | 27.63                           | 21.63    | 0.65     |
| Nodular type ECL cells in the corpus                     | 5.45                            | 6.40     | 0.71     |
| Gastrin cells in the antrum                             | 165.98                          | 160.83   | 0.69     |
| Gastrin cells in the corpus                             | 3.08                            | 5.30     | 0.34     |

The numbers of H⁺/K⁻-ATPase-positive cells, ECL cells, and gastrin cells were counted per each section. The size of each section was measured and the cell density was calculated per each section.

AIG autoimmune gastritis, H⁺/K⁻-ATPase hydrogen potassium ATPase, ECL cells enterochromaffin cell-like cells

*Comparison between florid and end stages; Mann-Whitney test

![Fig. 1](image)

**Fig. 1** Light microscopic pictures of the typical AIG cases in florid and end stages (H&E stain, low (a, c) and high (b, d) power magnifications). In the florid stage, the parietal cells are extensively reduced and persistent inflammation is observed (a). Parietal cells are under destruction (b: arrow). In the end stage, parietal cells are completely lost and inflammatory cell infiltrates are reduced (c). Pyloric-like glands are seen in the bottom of the mucosa (d). Scale bar: 200μm
positive cells were also found in greater curvature of the middle corpus in 14 cases (1 in florid and 13 in end stage), but the intensity of gastrin staining was weak in the corpus compared with that in the antrum (Fig. 3). The mean gastrin-positive cell density in the corpus was not significantly different between florid and end stages ($P=0.34$, Mann-Whitney test; Table 1). No gastric neoplasm such as carcinoma or neuroendocrine cell tumor was found in any of the cases.

**TFF2 expression in pyloric and pseudopyloric metaplasias**

TFF2 expression in pyloric and pseudopyloric metaplasias was examined in greater curvature of the middle corpus. Pyloric metaplasia was seen in all the cases, but pseudopyloric metaplasia was found in 15 cases (Table 2). TFF2-positive pyloric gland-like glands were found in 20 cases (Table 2). Pseudopyloric metaplasia was found in all the cases in florid stage, but not all in end stage. On the other hand, TFF2-positive glands were vice versa (Table 2).

There were 4 types of MUC6-positive metaplasia glands in the immunohistochemical stainings with PGI and TFF2 (Fig 4). Of 1567 pyloric gland–like glands in all the cases, 1381 (88.1%) glands were negative for PGI (pyloric metaplasia), and 186 (11.9%) glands were positive for PGI (pseudopyloric metaplasia). TFF2-positive and negative glands were found in both pyloric and pseudopyloric metaplasias. TFF2-positive glands were recognized in 409 of 1381 (26.9%) PGI-negative glands and 27 of 186 (14.5%) PGI-positive glands. There was a significant difference in the TFF2-positive gland ratio between PGI-negative and positive glands ($P<0.01$, chi-square test; Table 3). We also counted the numbers of pyloric gland–like glands with gastrin cells because gastrin-positive cells were found in greater curvature not only of the antrum but of corpus as mentioned above. Gastrin-positive cells in the corpus were seen in 58 of 1567 metaplasia glands. These gastrin-positive cells were only found in pyloric but not in pseudopyloric metaplasia glands. However, gastrin-positive cells were found irrespective whether the gland was TFF2-positive or not (Table 4).

**Discussion**

In this study, we clearly demonstrated that TFF2-positive glands (SPEM) were not always the same as PGI-positive mucosa in linear (black arrowhead) and nodular types (red arrowhead) in a case of florid stage (c, d). Pancreatic acinar cell metaplasia is found in the oxyntic mucosa of a case in end stage which showed BCL-10 positive (f black arrow), α-amylase vague (g red arrow), and H+/K+-ATPase negative (h). Scale bar 200μm.
glands (pseudopyloric metaplasia) and were overlapped with both PGI-positive and negative glands (Table 3). In addition, TFF2-positive glands were more frequently overlapped with PGI-negative than positive glands in the AIG patients (Table 3). In other words, TFF2 expression was more frequent with pyloric metaplasia than pseudopyloric metaplasia. Although SPEM has been considered synonymous with pseudopyloric metaplasia in many papers [16–20], it is confirmed that SPEM is not the same as pseudopyloric metaplasia.

Table 2 Numbers of cases containing each pyloric gland-like metaplasia in AIG

| Metaplasia       | Stage of AIG             | total |
|------------------|--------------------------|-------|
|                  | Florid stage (N = 4)     |       |
|                  | End stage (N = 18)       |       |
|                  | No. of cases | Ratio* | No. of cases | Ratio* | No. of cases | Ratio* |
| Pyloric           | 4 | 100.0% | 18 | 100.0% | 22 | 100.0% |
| Pseudopyloric     | 4 | 100.0% | 11 | 61.1% | 15 | 68.2% |
| TFF2 expression   | 2 | 50.0% | 18 | 100.0% | 20 | 90.9% |
| Number of cases   | 4 |       | 18 |       | 22 |       |

AIG autoimmune gastritis, TFF2 trefoil family factor 2

*Ratio of cases containing each metaplasia in each stage of AIG
From now, the terms pyloric metaplasia, pseudopyloric metaplasia, and SPEM should be used properly. Our results strongly support the opinion that SPEM is just a term proposed from animal studies, and we should not use SPEM for human materials because TFF2 expression in pyloric and pseudopyloric metaplasias is limited [15]. Or at least, when we use the concept of SPEM in humans, SPEM should not be considered the same as pseudopyloric metaplasia.

We also showed that gastrin-positive cells were not overlapped with PGI-positive glands, and PGI-positive glands were always gastrin-negative (Table 4). TFF2-positivity was not related to gastrin-positivity. These findings suggest that gastrin cells were produced in pyloric metaplasia but not in pseudopyloric metaplasia. Because TFF2 expression has nothing to do with gastrin cells, it is also consistent with that SPEM was independent to pyloric or pseudopyloric metaplasias.

In our AIG patients, the majority of pyloric gland-like metaplasia glands were PGI-negative (88.1%, Table 3). In addition, only 61.1% cases contained pseudopyloric metaplasia in end stage in spite that all the cases contained pseudopyloric metaplasia in the florid stage. It may suggest that some pseudopyloric metaplasia glands disappeared in the progression of atrophy and that pseudopyloric metaplasia may be observed only in the limited term. Or there is a possibility that pseudopyloric metaplasia glands might have changed into pyloric metaplasia glands with the progression of atrophy. These are very similar to the findings in the metaplasias in H. pylori gastritis. We recently reported that atrophy was more severe in the cases with pyloric metaplasia than in those with pseudopyloric metaplasia in H. pylori gastritis [4]. These findings suggest that pseudopyloric metaplasia occurs first in the process of atrophy and then changed to pyloric metaplasia according to the progression of atrophy.

On the other hand, TFF2 expression was vice versa (Table 2). TFF2 expression in AIG has not been studied much [36], but investigated in H. pylori gastritis [17]. Xia et al. reported that TFF2 expression was found more frequently in the cases with severe atrophy. These findings support that TFF2 expression may tend to occur in the cases with severe atrophy.

We have discussed AIG and its metaplasia, though, we should mention that this study has some limitations. First, the small number of subjects was studied because AIG was still uncommon in Asians including Japanese [37, 38]. Second, the metaplastic status of gastric mucosa might be affected by past H. pylori infection as well as AIG because past infected patients were included in this study.

However, the following conclusion could be drawn by quantitatively and closely observing metaplastic glands in each case; SPEM is not the same as pseudopyloric metaplasia in human AIG, and the majority of metaplasia in AIG is not pseudopyloric but pyloric metaplasia.

### Table 3

| Metaplasia         | TFF2 staining | Total   | Percent/total | TFF2-positive ratio* |
|--------------------|---------------|---------|---------------|---------------------|
|                    | +             | −       |               |                     |
| Pyloric (PGI−)     | 409           | 972     | 1381          | 88.1%              | 29.6%              |
| Pseudopyloric (PGI+) | 27         | 159     | 186           | 11.9%              | 14.5%              |
| Total              | 436           | 1131    | 1567          | 100.0%             |                    |

Pseudopyloric metaplasia was identified with PGI staining. The numbers of pyloric and pseudopyloric metaplasia glands were counted in all the 22 sections. Among them, the numbers of TFF2-positive and -negative glands were also counted.

TFF2 trefoil factor family 2, PGI pepsinogen I

*P<0.01, chi-square test

### Table 4

| PGI staining | Metaplasia | Gastrin staining | TFF2 staining |
|--------------|------------|-----------------|--------------|
| −            | Pyloric    | +               | 11           |
|              |            | −               | 398          |
| +            | Pseudopyloric | +           | 0            |
|              |            | −               | 27           |

The numbers of pyloric and pseudopyloric metaplasia glands with gastrin cells were counted in all the 22 sections. Among them, the numbers of TFF2-positive and -negative glands were also counted.

PGI pepsinogen I, TFF2 trefoil factor family 2
Supplementary Information  The online version contains supplementary material available at https://doi.org/10.1007/s00428-021-03033-5.

Acknowledgments  Sincere thanks are due to Ms. Naoko Taniura and Ms. Sanae Yamada for the help with immunochemical staining. We would also appreciate Emeritus Professor Takanori Hattori for the valuable advice.

Fig. 4  Light microscopic pictures of the four types of metaplasias in the serially sectioned slides: H&E (left pictures) and immunohistochemical stainings with anti-MUC6, PGI, and TFF2 (right 3 pictures). There were four types of glands in immunohistochemical stainings with anti-PGI and TFF2: PGI-/TFF2+ (a), PGI+/TFF2– (b), PGI+/TFF2+ (c), PGI+/TFF2– (d). Scale bar 200µm

Authors’ contributions  Yasuhiro Wada contributed to the study conception and design, data analysis, and wrote the manuscript. Shigemi Nakajima contributed to data collection and data analysis and revised the manuscript. Ryoji Kushima contributed to the study conception and design and data analysis and revised the manuscript. Shizuki Takemura contributed to data analysis and commented on the manuscript. Naoko Mori contributed to material preparation and data collection and commented on the manuscript. Hiroshi Hasegawa contributed to material
preparation and commented on the manuscript. Takahisa Nakayama contributed to data collection and commented on the manuscript. Ken-ichi Mukai had contributed to material preparation and commented on the manuscript. Shinji Umano contributed to the material preparation and commented on the manuscript. Kazuo Yamamoto contributed to the material preparation and commented on the manuscript. Hiroyuki Sugihara contributed to the data analysis and commented on the manuscript. Kazunari Murakami contributed to the study conception and design and commented on the manuscript.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Ethics approval** This study was approved by the Ethics Committee of JCHO Shiga Hospital (approval number: 2019-12) and Shiga University of Medical Science (approval number: R2019-157).

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Vinay K, Abul KA, Nelson F, Richard NM (2007) Robbins basic pathology. 8th edn. Saunders Elsevier, Philadelphia
2. Hattori T, Helpap B, Gedigk P (1982) The morphology and cell kinetics of pseudopyloric glands. Cell Pathol 39:31–40
3. Solcia E, Capella C, Fiocca R, Comaggia M, Rindi G, Villani L, Bosi F, Ambrosio L, (1990) Exocrine and endocrine epithelial changes in types A and B chronic gastritis. In: Malferttheiner P, Ditschuneit H (eds) Helicobacter pylori, Gastritis and Peptic Ulcer. Springer-Verlag, Berlin, pp 245–258
4. Wada Y, Kishima R, Kodama M, Fukuda M, Fukuda K, Okamoto K, Ogawa R, Mizukami K, Okimoto T, Murakami K (2020) Histological changes associated with pyloric and pseudopyloric metaplasia after Helicobacter pylori eradication. Virchows Arch 477:489–496
5. Krishnamurthy S, Dyal Y (1995) Pancreatic metaplasia in Barrett’s esophagus. An immunohistochemical study. Am J Surg Pathol 19: 1172–1180
6. Johansson J, Häkansson HO, Mellblom L, Kempar A, Kjellén G, Brudin L, Granath F, Johansson KE, Nyren O (2010) Pancreatic acinar metaplasia in the distal oesophagus and the gastric cardia: prevalence, predictors and relation to GORD. J Gastroenterol 45: 291–299
7. Schneider NJ, Piesschegner W, Geppert M, Wigglinghaus B, Höss GM, Eherer A, Wolf EM, Rehak P, Vieh M, Langner C (2013) Pancreatic acinar cells–a normal finding at the gastroesophageal junction? Data from a prospective Central European multicenter study. Virchows Arch 463:643–650
8. Wang TC, Goldring JR, Dangler C, Ito S, Mueller A, Jeon WK, Koh TJ, Fox JG (1998) Mice lacking secretory phospholipase A2 show altered apoptosis and differentiation with Helicobacter felis infection. Gastroenterology 114:675–689
9. Schmidt PH, Lee JR, Joshi V, Playford RJ, Poulsom R, Wright NA, Goldring JR (1999) Identification of a metastatic cell lineage associated with human gastric adenocarcinoma. Lab Invest 79: 639–646
10. Goldring JR, Nam KT (2010) Oxynotic atrophy, metaplasia, and gastric cancer. Prog Mol Biol Transl Sci 96:117–131
11. Hu GY, Yu BP, Dong WG, Li MQ, Yu JP, Luo HS, Rang ZX (2003) Expression of TFF2 and Helicobacter pylori infection in carcinogenesis of gastric mucosa. World J Gastroenterol 9:910–914
12. Halldórsdóttir AM, Sigurdardóttir M, Jónasson JG, Oódsdóttir M, Magnússon J, Lee JR, Goldring JR (2003) Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in Iceland. Dig Dis Sci 48:431–441
13. Yoshizawa N, Takenaka Y, Yamaguchi T, Tsukamoto T, Tanaka H, Tatematsu M, Nomura S, Goldring JR, Kaminishi M (2007) Emergence of spasmolytic polypeptide-expressing metaplasia in Mongolian gerbils infected with Helicobacter pylori. Lab Invest 87:1265–1276
14. Nam KT, O’Neal RL, Cotley RJ, Finke PE, Barker M, Goldring JR (2012) Spasmolytic polypeptide-expressing metaplasia (SPEM) in the gastric oxyntic mucosa does not arise from Lgr5-expressing cells. Gut 61:1678–1685
15. Graham DY, Zou WY (2018) Guilt by association: intestinal metaplasia does not progress to gastric cancer. Curr Opin Gastroenterol 34:458–464
16. Goldring JR (2018) Pyloric metaplasia, pseudopyloric metaplasia, ulcer-associated cell lineage and spasmolytic polypeptide-expressing metaplasia: reparative lineages in the gastrointestinal mucosa. J Pathol 245:132–137
17. Xia HH, Yang Y, Lan SK, Wong WM, Leung SY, Yuen ST, Elia G, Wright NA, Wong BC (2004) Abrupt epithelial expression of trefoil family factor 2 and mucin 6 in Helicobacter pylori infected gastric antrum, incisura, and body and its association with gastritis. J Clin Pathol 57:861–866
18. Fox JG, Rogers AB, Whary MT, Ge Z, Ohtani M, Jones EK, Wang TC (2007) Accelerated progression of gastritis to dysplasia in the pyloric antrum of TFF2-/-C57BL6 x Sv129 Helicobacter pylori-infected mice. Am J Pathol 171:1520–1528
19. Lennerz JK, Kim SH, Oates EL, Huh WJ, Doherty JM, Tian X, Bredemeyer AJ, Goldring JR, Lauwers GY, Shin YK, Mills JC (2010) The transcription factor MIST1 is a novel human gastric chief cell marker whose expression is lost in metaplasia, dysplasia, and carcinoma. Am J Pathol 177:1514–1533
20. Jin RU, Mills JC (2018) Are gastric and esophageal metaplasia relatives? The case for Barrett’s stemming from SPEM. Dig Dis Sci 63:2088–2041
21. Strickland RG, Mackay IR (1973) A reappraisal of the nature and significance of chronic atrophic gastritis. Am J Dig Dis 18:426–440
22. Callaghan JM, Khan MA, Aldenuccio F, Driel IR, Glessen PA, Toh BH (1993) Alpha and beta subunits of the gastric H+/K(+)ATPase are concordantly targeted by parietal cell autoantibodies associated with autoimmune gastritis. Autoimmunity 16:289–295
23. Karlsson FA, Barmann P, Lösf LC, Mården S (1988) Major parietal cell antigen in autoimmune gastritis with pernicious anemia is the acid-producing H+(K(+))-ATPase of the stomach. J Clin Invest 81:475–479
24. Stolte M, Baumann K, Bethke B, Ritter M, Laer M, Eidt H (1992) Active autoimmune gastritis without total atrophy of the glands. Z Gastroenterol 30:729–735
25. Bettington M, Brown I (2013) Autoimmune gastritis: novel clues to histological diagnosis. Pathology 45:145–149
26. Neumann WL, Coss E, Rugge M, Genta RM (2013) Autoimmune atrophic gastritis—pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol 10:529–541
27. Pittman ME, Voltaggio L, Bhaijee F, Robertson SA, Montgomery EA (2015) Autoimmune metaplastic atrophic gastritis: recognizing precursor lesions for appropriate patient evaluation. Am J Surg Pathol 39:1611–1620
28. Kulnigg-Dabsch S (2016) Autoimmune gastritis. Wien Med Wochenschr 166:424–430
29. Doglioni C, Laurino L, Dei Tos AP, Boni MD, Franzin G, Braidotti P, Viale G (1993) Pancreatic (acinar) metaplasia of the gastric mucosa. Histology, ultrastructure, immunocytochemistry, and clinicopathologic correlations of 101 cases. Am J Surg Pathol 17:1134–1143
30. Jhala NC, Montemor M, Jhala D, Lu L, Talley L, Haber MM, Lechago J (2003) Pancreatic acinar cell metaplasia in autoimmune gastritis. Arch Pathol Lab Med 127:854–857
31. Dixon MF, Genta RM, Yardley JH, Correa P (1996) Classification and grading of gastritis. The updated Sydney System. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol 20:1161–1181
32. Greenson JK, Lawers GY, Montgomery EA, Owens SR, Polydorides AD (2019) Diagnostic pathology; Gastrointestinal, 3rd edn. Elsevier, Amsterdam
33. Chlumská A, Boudová L, Benes Z, Zámečník M (2005) Autoimmune gastritis. A clinicopathologic study of 25 cases. Česk Patol 41:137–142
34. La Rosa S, Franzì F, Marchet S, Finzi G, Clerici M, Vigetti D, Chiavralli AM, Sessa F, Capella C (2009) The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia. Virchows Arch 454:133–142
35. Hosoda W, Sasaki E, Murakami Y, Yamao K, Shimizu Y, Yatabe Y (2013) BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens. Pathol Int 63:176–182
36. Jeong S, Choi E, Petersen CP, Roland JT, Federico A, Ippolito R, D’Armiento FP, Nardone G, Nagano O, Saya H, Romano M, Goldenring JR (2017) Distinct metaplastic and inflammatory phenotypes in autoimmune and adenocarcinoma-associated chronic atrophic gastritis. United European Gastroenterol J 5:37–44
37. Kim J, Kim MJ, Kho HS (2016) Oral manifestations in vitamin B12 deficiency patients with or without history of gastrectomy. BMC Oral Health 16:60
38. Kawanaka M, Tanikawa T, Kamada T, Ishii K, Urata N, Nakamura J, Nishino K, Suehiro M, Sasai T, Manabe N, Monobe Y, Kawamoto H, Haruma K (2019) High prevalence of autoimmune gastritis in patients with nonalcoholic steatohepatitis. Intern Med 58:2907–2913

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.